newsfilter
← Latest News
ACCESS Newswire·

Hillstream BioPharma Provides Business Review with Key Pipeline Updates

Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review Novel Emerging Pipeline on February 24, 2022 BRIDGE